Abstract
The phenomenon of sarcopenia, characterized by a progressive decline in skeletal muscle mass and function, epitomizes a significant aspect of the aging process. Current estimates suggest that sarcopenia affects approximately 50 million individuals globally, a figure projected to escalate to 500 million by 2050. This condition, often insidious in its onset, precipitates substantial functional impairments, elevating the risk of falls, disability, and mortality among the elderly. Consequently, sarcopenia substantially diminishes the quality of life for older adults and imposes a considerable burden on healthcare systems worldwide (Consensus of Diagnosis and Treatment of Sarcopenia in Chinese Older Adults, 2021) (Figure 1)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Immunology Research and Immunotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
